HRP20140315T1 - Modificirani enzimi lecitin-kolesterol aciltransferaze - Google Patents
Modificirani enzimi lecitin-kolesterol aciltransferaze Download PDFInfo
- Publication number
- HRP20140315T1 HRP20140315T1 HRP20140315AT HRP20140315T HRP20140315T1 HR P20140315 T1 HRP20140315 T1 HR P20140315T1 HR P20140315A T HRP20140315A T HR P20140315AT HR P20140315 T HRP20140315 T HR P20140315T HR P20140315 T1 HRP20140315 T1 HR P20140315T1
- Authority
- HR
- Croatia
- Prior art keywords
- substitution
- protein according
- modified
- lcat protein
- lcat
- Prior art date
Links
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 title claims 35
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 title claims 35
- 238000006467 substitution reaction Methods 0.000 claims 17
- 102220352428 c.92G>A Human genes 0.000 claims 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102200054153 rs121908015 Human genes 0.000 claims 3
- 102220572358 Myb/SANT-like DNA-binding domain-containing protein 4_C31W_mutation Human genes 0.000 claims 2
- 102220521924 THAP domain-containing protein 1_L32H_mutation Human genes 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102200062706 rs121908046 Human genes 0.000 claims 2
- 102220067346 rs138630815 Human genes 0.000 claims 2
- 102200071927 rs667782 Human genes 0.000 claims 2
- 102220543795 39S ribosomal protein L15, mitochondrial_P29L_mutation Human genes 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 102220530229 Beclin 1-associated autophagy-related key regulator_L32E_mutation Human genes 0.000 claims 1
- 102220473780 Beta-adrenergic receptor kinase 1_L4K_mutation Human genes 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 claims 1
- 208000006069 Corneal Opacity Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000023768 LCAT deficiency Diseases 0.000 claims 1
- 208000003465 Lecithin Cholesterol Acyltransferase Deficiency Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010034576 Peripheral ischaemia Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 102220593424 Protein PMS2CL_N34A_mutation Human genes 0.000 claims 1
- 102220617937 Putative uncharacterized protein LOC152225_G30V_mutation Human genes 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 102220521895 THAP domain-containing protein 1_L32A_mutation Human genes 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 229940127003 anti-diabetic drug Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 230000002785 anti-thrombosis Effects 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 102220377136 c.10C>A Human genes 0.000 claims 1
- 102220421646 c.83T>C Human genes 0.000 claims 1
- 231100000269 corneal opacity Toxicity 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 230000032050 esterification Effects 0.000 claims 1
- 238000005886 esterification reaction Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 102220236328 rs1131691720 Human genes 0.000 claims 1
- 102220008213 rs116840785 Human genes 0.000 claims 1
- 102220251505 rs1555201779 Human genes 0.000 claims 1
- 102220023098 rs387907466 Human genes 0.000 claims 1
- 102220042297 rs587780883 Human genes 0.000 claims 1
- 102200120772 rs876661123 Human genes 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT
Claims (21)
1. Modificirani protein lecitin-kolesterol aciltransferaza (LCAT), naznačen time što modificirani LCAT protein sadrži modifikaciju aminokiselinske sekvence zrelog LCAT navedenog u SEQ ID NO: 1; ili SEQ ID NO: 2 kao što je navedena na Sl. 2; i modifikacija se sastoji od supstitucije na aminokiselinskom ostatku C31 izabranom iz grupe koju čine C31I, C31M, C31F, C31V, C31W, C31Y, C31R i C31H.
2. Modificirani protein lecitin-kolesterol aciltransferaza (LCAT), naznačen time što modificirani LCAT protein sadrži modifikaciju aminokiselinske sekvence zrelog LCAT navedenog u SEQ ID NO: 1; ili SEQ ID NO: 2 kao što je navedena na Sl. 2; i modifikacija se sastoji od supstitucije na aminokiselinskom ostatku C31 izabranom iz grupe koju čine C31I, C31M, C31F, C31V, C31W, C31Y, C31R i C31H, i dodatne supstitucije na položaju aminokiselinskog ostatka izabranom iz grupe koju čine F1, L4, N5, V28, P29, G30, L32, G33 i N34.
3. Modificirani LCAT protein prema patentnom zahtjevu 2, naznačen time što je dodatna supstitucija izabrana iz grupe koju čine F1A, L4F, N5E, N5Q, N5D, N5A, V28A, V281, V28C, V28T, V28R, P29G, P29F, P29T, G30A, G30I, L32A, L321, L32M, L32F, L32C, L32W, L32Y, L32T, L32S, L32N, L32H, L32E, G331, G33M, G33F, G33S, G33H, N34A, N34C, N34S i N34R.
4. Modificirani LCAT protein prema patentnom zahtjevu 2, naznačen time što, C31 supstitucija je C31Y supstitucija i dodatna supstitucija je na položaju aminokiselinskog ostatka koji je izabran iz grupe koju čine F1, L4, N5, L32 i N34.
5. Modificirani LCAT protein prema patentnom zahtjevu 4, naznačen time što je dodatna supstitucija izabrana iz grupe koju čine F1S, F1W, L4F, L4M, N5D, L4K, N34S, L32F i L32H.
6. Modificirani LCAT protein prema patentnom zahtjevu 5, naznačen time što sadrži L4F supstituciju i C31Y supstituciju.
7. Modificirani LCAT protein prema patentnom zahtjevu 5, naznačen time što sadrži C31Y supstituciju, pri čemu je dodatna supstitucija N5D supstitucija.
8. Modificirani LCAT protein prema patentnom zahtjevu 4, naznačen time što sadrži N5 supstituciju i C31Y supstituciju.
9. Modificirani LCAT protein prema patentnom zahtjevu 4, naznačen time što sadrži L4 supstituciju i C31Y supstituciju.
10. Modificirani LCAT protein prema bilo kojem od patentnih zahtjeva 1-9, naznačen time što ima enzimsku aktivnost veću od LCAT proteina divljeg tipa naveden u SEQ ID NO: 1 ili SEQ ID NO: 2 kao što je određena u testu aktivnosti LCAT u plazmi - stope esterifikacije kolesterola (CER).
11. Modificirani LCAT protein koji sadrži LCAT protein prema bilo kojem od patentnih zahtjeva 1-10 i nosač.
12. Modificirani LCAT protein prema patentnom zahtjevu 11, naznačen time što je nosač izabran iz grupe koju čine konstantna regija imunoglobulina (Fc), polimer topljiv u vodi i polietilen glikol.
13. Farmaceutska kompozicija koja sadrži modificirani LCAT protein prema bilo kojem od patentnih zahtjeva 1-12 i farmaceutski prihvatljiv nosač.
14. Modificirani LCAT protein prema bilo kojem od patentnih zahtjeva 1-12 za uporabu u liječenju.
15. Modificirani LCAT protein prema bilo kojem od patentnih zahtjeva 1-12, za uporabu u postupku za liječenje poremećaja povezanog sa LCAT.
16. Modificirani LCAT protein prema patentnom zahtjevu 15 za uporabu u postupku za liječenje poremećaja povezanog sa LCAT, pri čemu je poremećaj povezan sa LCAT izabran iz grupe koju čine ateroskleroza, inflamacija, tromboza, koronarna srčana bolest, visok krvni tlak, sindrom deficijencije LCAT, Alzhajmerova bolest, neprozirnost rožnjače, metabolički sindrom, dislipidemija, infarkt miokarda, moždani udar, kritična ishemija uda i angina.
17. Modificirani LCAT protein prema patentnom zahtjevu 15, naznačen time što je liječenje za povećanje HDL kolesterola, ili prevenciju akumulacije kolesterola.
18. Modificirani LCAT protein prema patentnom zahtjevu 15 za uporabu u postupku za liječenje ili prevenciju kardiovaskularne bolesti.
19. Modificirani LCAT protein prema patentnom zahtjevu 15 za uporabu u liječenju ili prevenciji ateroskleroze.
20. Modificirani LCAT protein prema bilo kojem od patentnih zahtjeva 15-19, naznačen time što se modificirani LCAT protein primjenjuje u kombinaciji sa dodatnim sredstvom.
21. Modificirani LCAT protein prema patentnom zahtjevu 20, naznačen time što je dodatno sredstvo izabrano iz grupe koju čine citokin, lijek za aterosklerozu, lijek za snižavanje kolesterola, inhibitor ACE, anti-inflamatorni lijek i lijek protiv tromboze i anti-dijabetički lijek.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95200707P | 2007-07-26 | 2007-07-26 | |
| PCT/US2008/071119 WO2009015314A2 (en) | 2007-07-26 | 2008-07-25 | Modified lecithin-cholesterol acyltransferase enzymes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140315T1 true HRP20140315T1 (hr) | 2014-05-09 |
Family
ID=39864722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140315AT HRP20140315T1 (hr) | 2007-07-26 | 2014-04-01 | Modificirani enzimi lecitin-kolesterol aciltransferaze |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US8168416B2 (hr) |
| EP (4) | EP2489730B1 (hr) |
| JP (5) | JP5643643B2 (hr) |
| KR (1) | KR20100040937A (hr) |
| CN (1) | CN101855344B (hr) |
| AU (1) | AU2008279065B2 (hr) |
| BR (1) | BRPI0814310A2 (hr) |
| CA (1) | CA2694590A1 (hr) |
| CR (1) | CR11272A (hr) |
| CY (2) | CY1114857T1 (hr) |
| DK (2) | DK2489731T3 (hr) |
| EA (1) | EA201070187A1 (hr) |
| ES (3) | ES2513716T3 (hr) |
| HK (1) | HK1138039A1 (hr) |
| HR (1) | HRP20140315T1 (hr) |
| IL (1) | IL203399A0 (hr) |
| MX (1) | MX348799B (hr) |
| MY (1) | MY159075A (hr) |
| NZ (2) | NZ582794A (hr) |
| PL (2) | PL2489731T3 (hr) |
| PT (2) | PT2489731E (hr) |
| RS (1) | RS53237B (hr) |
| SG (1) | SG186016A1 (hr) |
| SI (2) | SI2181190T1 (hr) |
| UA (1) | UA103304C2 (hr) |
| WO (1) | WO2009015314A2 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201070187A1 (ru) * | 2007-07-26 | 2010-08-30 | Эмджен Инк. | Модифицированные ферменты лецитин-холестерин ацилтрансферазы |
| JP5759988B2 (ja) * | 2009-06-12 | 2015-08-05 | アルファコア ファーマ リミテッド ライアビリティ カンパニーＡｌｐｈａｃｏｒｅ Ｐｈａｒｍａ Ｌｌｃ | 貧血および赤血球機能不全を治療するためのｌｃａｔの使用 |
| AU2011247985B2 (en) | 2010-05-06 | 2015-12-03 | Alphacore Pharma Llc | Delivery of cholesteryl ester to steroidogenic tissues |
| EP2701732B1 (en) * | 2011-02-25 | 2017-08-30 | University Of Patras | Lecithin:cholesterol acyltransferase (lcat) and its role in nonalcoholic fatty liver disease (nafld) |
| AU2012250614B2 (en) * | 2011-05-05 | 2016-02-11 | Pharma Cinq, Llc | Complement factor B analogs and their uses |
| CN104220460A (zh) | 2011-12-08 | 2014-12-17 | 安姆根有限公司 | 激动人lcat抗原结合蛋白和它们在疗法中的用途 |
| WO2016123569A2 (en) * | 2015-01-29 | 2016-08-04 | Plantvax, Inc. | Highly expressed protective plant-derived broadly neutralizing hiv monoclonal antibodies for use in passive immunotherapy |
| US11883470B2 (en) | 2016-07-25 | 2024-01-30 | The Trustees Of The University Of Pennsylvania | Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof |
| EP3706781A4 (en) * | 2017-11-07 | 2021-07-21 | Alphacore Pharma LLC | METHODS OF TREATMENT AND PROTECTION AGAINST HEART DISEASE, CARDIOVASCULAR DISEASE AND ASSOCIATED CONDITIONS AND SYMPTOMS |
| US20210115412A1 (en) * | 2018-05-22 | 2021-04-22 | Dsm Ip Assets B.V. | Modified sterol acyltransferases |
| US11612619B2 (en) | 2018-11-01 | 2023-03-28 | National Institute Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government | Compostions and methods for enabling cholesterol catabolism in human cells |
| KR200493485Y1 (ko) * | 2019-08-27 | 2021-04-07 | 주식회사 서원기술 | 배관용 고무링 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| JPS63167409A (ja) | 1986-12-27 | 1988-07-11 | Yamaha Corp | 磁気記録体 |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| DE10199003I1 (de) | 1987-09-04 | 2003-06-12 | Beecham Group Plc | Substituierte Thiazolidinionderivate |
| US6288095B1 (en) | 1987-09-04 | 2001-09-11 | Beecham Group P.L.C. | Compounds |
| DE3889853D1 (de) | 1987-11-05 | 1994-07-07 | Hybritech Inc | Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. |
| GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1992016192A1 (en) | 1991-03-15 | 1992-10-01 | Amgen Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| HU9203780D0 (en) | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
| EP0636156B1 (en) | 1992-04-14 | 1997-07-30 | Cornell Research Foundation, Inc. | Dendritic based macromolecules and method of production |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US5741803A (en) | 1992-09-05 | 1998-04-21 | Smithkline Beecham Plc | Substituted thiazolidinedionle derivatives |
| EP0680320B1 (en) | 1993-01-19 | 1999-04-14 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| BR9609872A (pt) | 1995-07-17 | 1999-03-23 | Warner Lambert Co | Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino |
| ATE353957T1 (de) * | 1995-11-09 | 2007-03-15 | Us Gov Health & Human Serv | Verwendung von lezithin-cholesterin- azetyltransferase für die behandlung von atherosklerose |
| EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| FR2758459B1 (fr) | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
| DE69836626T2 (de) * | 1997-04-11 | 2007-04-05 | Takeda Pharmaceutical Co. Ltd. | Proteine mit lecithin-cholesterin acetyltransferase-ähnlicher aktivität, deren herstellung und verwendung |
| ATE250418T1 (de) | 1998-07-15 | 2003-10-15 | Merck Sante Sas | Tabletten enthaltend eine kombination von glibenclamid und metformin |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| WO2001005943A2 (en) | 1999-07-14 | 2001-01-25 | Betagene, Inc. | Lcat recombinant cell line compositions and methods |
| WO2008002591A2 (en) * | 2006-06-26 | 2008-01-03 | Amgen Inc | Methods for treating atherosclerosis |
| EA201070187A1 (ru) * | 2007-07-26 | 2010-08-30 | Эмджен Инк. | Модифицированные ферменты лецитин-холестерин ацилтрансферазы |
-
2008
- 2008-07-25 EA EA201070187A patent/EA201070187A1/ru unknown
- 2008-07-25 AU AU2008279065A patent/AU2008279065B2/en not_active Ceased
- 2008-07-25 MY MYPI2010000370A patent/MY159075A/en unknown
- 2008-07-25 PL PL12003811T patent/PL2489731T3/pl unknown
- 2008-07-25 SG SG2012085213A patent/SG186016A1/en unknown
- 2008-07-25 PL PL08796592T patent/PL2181190T3/pl unknown
- 2008-07-25 JP JP2010518400A patent/JP5643643B2/ja not_active Expired - Fee Related
- 2008-07-25 KR KR1020107003535A patent/KR20100040937A/ko not_active Application Discontinuation
- 2008-07-25 SI SI200831169T patent/SI2181190T1/sl unknown
- 2008-07-25 CN CN200880109092.XA patent/CN101855344B/zh not_active Expired - Fee Related
- 2008-07-25 SI SI200831324T patent/SI2489731T1/sl unknown
- 2008-07-25 BR BRPI0814310 patent/BRPI0814310A2/pt not_active Application Discontinuation
- 2008-07-25 PT PT12003811T patent/PT2489731E/pt unknown
- 2008-07-25 ES ES12003811.2T patent/ES2513716T3/es active Active
- 2008-07-25 EP EP12003810.4A patent/EP2489730B1/en active Active
- 2008-07-25 NZ NZ58279408A patent/NZ582794A/xx not_active IP Right Cessation
- 2008-07-25 EP EP12003809.6A patent/EP2522721B1/en active Active
- 2008-07-25 DK DK12003811T patent/DK2489731T3/en active
- 2008-07-25 MX MX2014001593A patent/MX348799B/es unknown
- 2008-07-25 PT PT08796592T patent/PT2181190E/pt unknown
- 2008-07-25 CA CA 2694590 patent/CA2694590A1/en not_active Abandoned
- 2008-07-25 ES ES12003810.4T patent/ES2559353T3/es active Active
- 2008-07-25 EP EP20120003811 patent/EP2489731B1/en active Active
- 2008-07-25 ES ES08796592T patent/ES2449483T3/es active Active
- 2008-07-25 EP EP20080796592 patent/EP2181190B1/en active Active
- 2008-07-25 DK DK08796592T patent/DK2181190T3/da active
- 2008-07-25 UA UAA201002094A patent/UA103304C2/ru unknown
- 2008-07-25 WO PCT/US2008/071119 patent/WO2009015314A2/en active Application Filing
- 2008-07-25 US US12/179,815 patent/US8168416B2/en active Active
- 2008-07-25 RS RSP20140148 patent/RS53237B/en unknown
- 2008-07-25 NZ NZ59788508A patent/NZ597885A/xx not_active IP Right Cessation
-
2010
- 2010-01-19 IL IL203399A patent/IL203399A0/en unknown
- 2010-02-12 CR CR11272A patent/CR11272A/es unknown
- 2010-05-13 HK HK10104660A patent/HK1138039A1/xx not_active IP Right Cessation
-
2012
- 2012-04-04 US US13/439,428 patent/US8703926B1/en active Active
-
2014
- 2014-02-18 CY CY20141100119T patent/CY1114857T1/el unknown
- 2014-03-04 US US14/196,827 patent/US9006408B2/en active Active
- 2014-04-01 HR HRP20140315AT patent/HRP20140315T1/hr unknown
- 2014-06-25 JP JP2014130551A patent/JP6033258B2/ja not_active Expired - Fee Related
- 2014-09-19 CY CY20141100767T patent/CY1115573T1/el unknown
-
2016
- 2016-06-23 JP JP2016124506A patent/JP2016182136A/ja active Pending
-
2018
- 2018-06-05 JP JP2018107669A patent/JP2018161134A/ja active Pending
-
2019
- 2019-12-18 JP JP2019228172A patent/JP2020058366A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140315T1 (hr) | Modificirani enzimi lecitin-kolesterol aciltransferaze | |
| JP2010534479A5 (hr) | ||
| BR0214794A (pt) | sistema para melhorar a saúde da pele de usuários de artigo absorvente | |
| NO20082498L (no) | Diarylurea for behandling av pulmonar hypertensjon | |
| Shaw | The next wave of influenza drugs | |
| BR9915919A (pt) | Proteìnas terapeuticamente ativas em plantas | |
| ATE351901T1 (de) | Neue methoden und interferon defiziente substrate zur vermehrung von viren | |
| WO2010046291A3 (de) | Verwendung von hyroxyzimtsäuren und ihren derivaten und/oder von pflanzenextrakten zur behandlung von körpergeruch | |
| WO2007122580A3 (en) | Compositions of phenylephrine useful for treatment of respiratory illness | |
| GEP20104960B (en) | USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN | |
| BR112014013250A2 (pt) | compostos com enzima alvo e usos dos mesmos | |
| WO2008015249A3 (en) | Cosmetic or pharmaceutical composition containing hyaluronic acid | |
| WO2010115700A3 (de) | Pulverförmige zusammensetzung zur form- und glanzgebung keratinischer fasern | |
| BR112014013161A2 (pt) | compostos com enzima lisossomal alvo | |
| HUP0401614A2 (hu) | PDE4 inhibitort és antikolinerg hatóanyagot tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| WO2006128100A3 (en) | Chondrogenic compositions and methods of use | |
| JP2021006522A (ja) | 被膜形成性皮膚外用組成物 | |
| PE20000065A1 (es) | Combinaciones de inhibidor de ace-inhibidor de mmp | |
| GEP20043285B (en) | Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections | |
| CL2004000806A1 (es) | Compuestos derivados de quinazolinas, inhibidores de quinasa p38, composicion farmaceutica, procedimiento de preparacion, utiles para tratar artritis, enfermedad de crohn, alzheimer, asma, ataque al corazon, sepsis, infarto al miocardio y otras. | |
| WO2012084879A3 (de) | Kosmetisches reinigungsmittel | |
| WO2002074719A8 (en) | Inhibitors of plasmepsins | |
| Nakahata et al. | Structural and inhibitory properties of a plant proteinase inhibitor containing the RGD motif | |
| BR0010034A (pt) | Utilização de um vetor, processo de preparação de um medicamento útil para a prevenção, a melhoria e/ou o tratamento da hipertensão arterial pulmonar, e, composição farmacêutica | |
| JP6552079B2 (ja) | 頭臭抑制用組成物 |